Group 1 - The core viewpoint of the news is the performance and financial status of Beijing Baipusi Biotechnology Co., Ltd., which saw a stock price increase of 5.07% to 56.74 CNY per share, with a total market capitalization of 9.486 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] Group 2 - From the perspective of fund holdings, Guotai Fund has a significant position in Baipusi, with the Guotai Innovation Medical Mixed Fund A (018159) holding 21,600 shares, representing 5.2% of the fund's net value, making it the seventh-largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 17.7778 million CNY, and has achieved a year-to-date return of 38.09%, ranking 2210 out of 8155 in its category [2] Group 3 - The fund manager of Guotai Innovation Medical Mixed Fund A is Qiu Xiaoxu, who has been in the position for 3 years and 144 days, managing assets totaling 676 million CNY, with the best fund return during the tenure being 5.58% and the worst being 0.5% [3]
百普赛斯股价涨5.07%，国泰基金旗下1只基金重仓，持有2.16万股浮盈赚取5.92万元